Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Thanks - they need money so shelf offering was expected - so dilution will happen but will help operations.
What happened here?
Any big bad news?
Where is the interview? Can you give the link?
Some news - they raised money ($6.5 Million) and now approval to drill 12 well to unrestricted depth. They have to plan and execute
—————-
The ECC authorizes ReconAfrica to commence the drilling of an additional 12 exploration and appraisal wells, to unrestricted depths, in the Kavango Basin, in Namibia from July 4, 2023, until July 4, 2026.
The primary objective of the upcoming drilling program is to establish commercial accumulations of oil and or natural gas and natural gas liquids which were identified in the first three stratigraphic test wells.
Management's current focus in the 3rd & 4th quarter of 2023 is developing and prioritizing its prospect inventory in order to execute a multi-well drilling program targeting both primary plays; the Damara Fold Belt and the Karoo Rift Basin, with initial emphasis on the Damara Fold Belt as detailed in the Company's June 26, 2023, news release.
That is BS
My friend’s company pays $5000 per employee whose name appears on the patent. Plus their yearly stock option amount increases based on utility of the patent to the companies product line.
Employees well rewarded at expense of shareholders who do not get anything
Anavex - very high salary
Anavex Life Sciences: $674,500
https://flip.it/4dFp6I The 7 best-paying biopharma companies where workers can take home more than $400,000
The good news is - the company gives updates as promised
The not so good news - all these updates do not mean much till some concrete results are announced.
We need some positive statements from the company showing that the area (very large) contains some decent amount of oil that can be extracted logically
This company executes the plan but no good results - we have to wait to see how their commercial launch goes
I agree - I will be happy if they are able to conduct the trial using Chinese protocol and make it a success in US as well
That is good news for Oramed - not sure what they will get it - some royalty
Maybe they did not set up study parameters correctly. Now they have to start from scratch - maybe some BP will buy them
I am completely out of this stock and already booked a lot of losses
AVXL will be lucky to apply for NDA in Q1 2924
Provided they have clean approvals data on hand and they do not have such data
No one seem to believe it
For going to commercialization - there are many steps and of them is to publish full data and at some point submit NDA and then 9 months for approval - so hold your horses
No one asked you to believe
But people were saying Anavex now in 2017 as well but nothing has happened and product is not approved
M has not even given detailed analysis as well
Keep on dreaming
You are believing a person who has missed nearly every milestone that he personally announced.
He will come with some escape route to say that what we said was correct but it does not meet what FDAneeds and we need larger trials
It is showing results and they have large sample. Look at the sample size - AVXL does not stand any chance to even consider going to FDA for approval. They will need at least one large trial (LLY has 2 trials going on)
In short - add 4 to 5 years for AD approval - Missling will milk the company and make money
—-
In the primary analysis population (n=1182), the main goal (iADRS) showed 35% slowing of decline, compared to placebo.
Meanwhile, an important secondary goal (Clinical Dementia Rating-Sum of Boxes (CDR-SB) - a measure of disease severity) showed 36% slowing of decline over 18 months.
—-
Based on current progress - AVXL will not get any revenue before 2025
Company is doing OK in terms of work and providing updates.
The work they are doing is very comprehensive. Whether they find oil is not in their control but their efforts are well directed. Hope we see some results
“Once acquired and processed, the 2,200 sq km survey will be integrated with the Company's existing 2D seismic data, which greatly enhances ReconAfrica's capacity to extrapolate structural geometry in three dimensions”
https://seekingalpha.com/article/4594258-verona-pharma-ensifentrine-vs-dupixent-ensifentrine-is-a-breath-of-fresh-air
Firstly, in the Phase 3 ENHANCE-1 and ENHANCE-2 trials, ensifentrine reported a 36% and 42% pbo-adjusted reduction in COPD exacerbation at week 24, respectively. In contrast, dupixent demonstrated a 30% pbo-adjusted reduction in COPD exacerbation at week 52 in the BOREAS trial.
Verona Pharma is expected to submit an NDA by 1H 2023, PDUFA by 1H 2024, and launch in the US by 2H 2024.
You will find this article interesting -
The phrase “correlation does not imply causation” is often used in statistics to point out that correlation between two variables does not necessarily mean that one variable causes the other to occur.
https://www.statology.org/correlation-does-not-imply-causation-examples/
He has milked this cow so much - he thinks his days are done here
In my view - Anavex does not have much in-house knowledge or knowledgeable people
They got 2 compounds and they trialing it for years without going much further
Missling likes to talk about some key words and concepts but A2-73 not proven anything. So they are not in a position to prove if A2-73 works.
A3-71 is a mystery and as they say a treasure is worth millions of dollars till it is hidden in a box and not found. Once the box is discovered and opened it may be worth $100 - so Missling will go slow till he can keep on saying that it is more effective than A2-73
https://flip.it/-N2BMe
Scientists discover the cause of Alzheimer’s disease - affecting millions of people worldwide
the researchers discovered that a protein in lysosomes called PLD3 caused these organelles to grow and clump together along axons, eventually leading to the swelling of axons and the breakdown of electrical conduction.
https://flip.it/YCg1vp
Richard Engel’s son died of Rett syndrome. His cells may help find a cure, his doctor says.
https://flip.it/EQwmTE
Mitochondrial Dysfunction May Be a Cause of Age-Related Cognitive Impairment
We found that synaptic loss occurred with healthy and impaired aging, but what differed was the breakdown in the correlation between the sizes of boutons and their mitochondria.”
The report looks good - they provide updates regularly - I like transparency
There seems to be delays in drilling new well 5-1
——
“The earlier phase of 2D seismic combined with stratigraphic test wells which penetrated the underlying Damara section (pre-Karoo aged stratigraphy), initially identified the fold belt below the Karoo Rift Basin and confirmed the trend and presence of these fold structures, carbonate reservoir rocks with up to 17% matrix porosity, fracture porosity, and significant oil shows (Netherland, Sewell & Associates Report). “
https://flip.it/LGfhsf
Alzheimer's May Not Actually Be a Brain Disease, Expert Says
Haha - the PR is clumsy and does not indicate it. Market does not have much faith as well.
Rett - ACAD already got approval and it’s price has not appreciated so that tell Rett story.
Good luck for dreams
How will you hold him accountable?
This topic has been discussed for last 5-6 years - he operates same way - misleading information, missed milestones, incomplete and/or misleading information.
This has happened year after year and no one could and can do a shxt about it
Seems an interesting play in ADC
https://flip.it/x3q2Je
Researchers discover major new contributor to Alzheimer's disease
In this study, the researchers detail the pathway of BF-LPS from the gut to the brain and its mechanisms of action once there. BF-LPS leaks out of the GI tract, crosses the blood brain barrier via the circulatory system, and accesses brain compartments. Then it increases inflammation in brain cells and inhibits neuron-specific neurofilament light (NF-L,) a protein that supports cell integrity.
A deficit of this protein leads to progressive neuronal cell atrophy, and ultimately cell death, as is observed in AD-affected neurons. They also report that adequate intake of dietary fiber can head off the process.
The novel features of this newly described pathological pathway are threefold. The AD-stimulating pathway begins inside of us – in our GI-tract microbiome - and therefore is very “locally sourced” and active throughout our lives. The highly potent neurotoxin BF-LPS is a natural by-product of GI-tract-based microbial metabolism. Bacteroides fragilis abundance in the microbiome, which is the source of the neurotoxin BF-LPS, can be regulated by dietary fiber intake.
https://flip.it/P0ljvi
A new mitochondrial theory of Alzheimer's deserves serious attention
https://flip.it/..FFdX
A new mitochondrial theory of Alzheimer's deserves serious attention
The boards became cult and started drinking cool aide and started giving free pass to CEO. There was no control on CEO from board and the posters kept of posting crazy unrealistic expectations that never came true.
AVXL board is showing same signs
When boards become cult boards - look at what has become of IPIX and CYDY
Blind faith in the CEO - who misses all the milestones and promises next milestones without consequences - no phase 3 approved in 6-7 years - CEO earns hefty salary and bonus and stock options
In the end, the stock becomes penny stock - CEO is removed but he has earned his millions and SH become poor shareholders with no one to answer what went wrong
As per the knowledgeable people here - A2-73 is so great that for AD or Rett, FDA will give approval based on P2 results only.
A2-73 is so exceptional that FDA will make exception to all their rule and just approve it. They will approve it even if M does not file NDA.
Since 2019-20 A2-73 was supposed to be approved immediately - but cabal influenced FDA and did not allow to approve it
A chocolate box with expiry date
Time will tell - I maintain that all the posts are pure speculative based on what each person thinks he/she understands about the drug or trial or the available data.
At this point except for M, no one here knows anything more than what PR said. So my guess is good as anyone else. Only time will tell whose guess was more accurate
Good detailed analysis
I have come to the same conclusion and maintained the same view that another P3 will be required but my conclusion was based on much simpler approach -
- the results were not conclusive
- M was presenting data in selective way to make it look good
- the trial had 2 doses and number of patients around 170 for each dose is too small and non-conclusive for FDA to even considering approval of either dose.
AVXL will need another large P3 trial - 1000 patients where they have to use a single dose that they want to recommend for approval and get concrete results to that the dose and drug works.